Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment

Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment

Immune checkpoint blockade (ICB) therapy targeting the programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) axis has achieved considerable success in treating a wide range of cancers. However, most patients with pancreatic cancer remain resistant to ICB. Moreover, there is a lack of optimal bio...

Full description

Bibliographic Details
Main Authors: Zhiqing Lin, Keke Huang, Hui Guo, Manli Jia, Qiuqin Sun, Xuhao Chen, Jianmin Wu, Qingqing Yao, Peng Zhang, Sergii Vakal, Zhengzhi Zou, Haiyao Gao, Lei Ci, Jiangfan Chen, Wei Guo
Format: Article
Language:English
Published: Elsevier 2023-05-01
Series:Biomedicine & Pharmacotherapy
Subjects:
ZDHHC9
Pancreatic cancer
Immunotherapy
Tumor microenvironment
Nanoparticle
PD-L1
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332223003554

Internet

http://www.sciencedirect.com/science/article/pii/S0753332223003554

Similar Items